Sepin Biotech

What Sepin Biotech does

Sepin Biotech is a privately held, Houston-based biotechnology research firm with a stated headcount of 1–10 employees. According to the available firmographic profile, the company's research focus spans cancer studies and RNA-related work, though no specific programs, pipeline assets, therapeutic targets, modalities, or scientific publications are publicly disclosed in the source material.

No products, services, core technology platforms, proprietary tools, or intellectual property (patents, trademarks) are disclosed in the input data. The only verifiable public-facing asset referenced is the domain sepin-biotech.com, which was registered on 06/07/2018, first appeared in the Wayback Machine in 2021, accumulated 292 indexed pages across 8 crawls, and has since expired; it is currently listed for sale on GoDaddy at a USD 195 buy-now price. No founding date, management team, investors, funding history, subsidiary structure, or parent-company relationships are disclosed.

No revenue model, pricing, customer segments, go-to-market motion, marketing channels, distribution channels, strategic customers, partnerships, certifications, regulatory actions, awards, certifications, or geographic operating footprint are documented in the available sources. The operating status is reported as 'operating,' but this is inferred from the absence of a closure event rather than from any positive operating signal such as active product revenue, ongoing trials, published research, or recent capital raises. As a result, the company is effectively a data-thin profile: name, location, headcount band, and research-area claim, with no substantive operational, financial, or commercial evidence.

Name

Sepin Biotech

Website

https://sepin-biotech.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Sepin Biotech is a Houston-based, privately held biotechnology research firm with 1–10 employees focused on cancer studies and RNA-related work. No products, customers, or financial details are publicly disclosed, and the company's web domain has expired.

Ownership category

akta.pro rank

Product category

Biotechnology Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro industry

PRIMARYHLAGANAE

Transcriptomics & Gene Expression Profiling Services

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

• Biotechnology research
• Cancer research studies
• RNA biology research
• Molecular biology studies
• Life sciences research

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Core offering

Sepin Biotech is a Houston, Texas-based biotechnology research entity focused on cancer studies and RNA biology. The firm is a privately held for-profit organization with 1-10 employees, and its stated activity centers on biotechnology research areas including oncology and RNA-related studies.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Emerging players

• ProQR Therapeutics: ProQR is developing RNA-editing and RNA-targeted therapies for genetic diseases, with a research platform that intersects with Sepin Biotech's RNA focus.
• MiNA Therapeutics: MiNA Therapeutics is a clinical-stage biotech developing RNA activation (RNAa) therapeutics, with oncology as a key area. Comparable as a smaller RNA-focused peer.
• Arcturus Therapeutics: Arcturus focuses on mRNA medicines and RNA-based technologies with applications in vaccines and rare diseases, including oncology-adjacent programs. Comparable as a smaller RNA-focused peer.

Direct peers

• Alnylam Pharmaceuticals: Alnylam is a leading RNAi therapeutics company developing RNA-based drugs for serious diseases, including oncology indications. It is directly comparable to Sepin Biotech's stated focus on RNA research and cancer studies.
• CureVac: CureVac is an mRNA technology company developing therapeutics and vaccines, with oncology applications. Directly comparable in RNA therapeutics focus to Sepin Biotech.
• Moderna: Moderna is an mRNA therapeutics and vaccines company with oncology programs in its pipeline. It is a high-relevance peer given Sepin Biotech's focus on RNA and cancer research.
• Ionis Pharmaceuticals: Ionis pioneered antisense oligonucleotide (RNA-targeted) therapeutics and has a broad pipeline spanning oncology, neurology, and rare diseases. It directly overlaps with Sepin Biotech's RNA research and cancer focus.
• Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapies across multiple disease areas, including oncology. Its RNA-targeted platform and cancer pipeline are directly relevant to Sepin Biotech's stated focus.
• BioNTech: BioNTech is an mRNA-based therapeutics company with significant oncology vaccine and immunotherapy programs. Directly comparable to Sepin Biotech's RNA and cancer research profile.
• Translate Bio (now part of Sanofi): Translate Bio was an mRNA therapeutics developer (acquired by Sanofi) focused on vaccines and therapeutics, including cystic fibrosis and other indications. Relevant as an RNA-focused peer.

Market position

Strengths3 records

Weaknesses3 records

Key risks5 records

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sepin Biotech